SCHEMBL19852956

SCHEMBL19852956

O=S(=O)(Nc1cccc2cnccc12)c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.69
IDO1 P14902 1/20 0.62
KMT2A Q03164 3/20 0.61
MEN1 O00255 2/20 0.61
ALDH1A1 P00352 1/20 0.61
MAPT P10636 1/20 0.61
SLC40A1 Q9NP59 6/20 0.57
GLO1 Q04760 3/20 0.57
AGTR1 P30556 2/20 0.57
PAX8 Q06710 2/20 0.57
G6PD P11413 1/20 0.57
NFKBIA P25963 1/20 0.57
METAP2 P50579 1/20 0.57
METAP1 P53582 1/20 0.57
ATM Q13315 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
DDX3X O00571 1/20 0.52
IMPDH2 P12268 1/20 0.50
NAMPT P43490 1/20 0.50
TRPV1 Q8NER1 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17737766 0.92 IDO1 (0.61) RECQLIDO1KMT2AMEN1ALDH1A1
SCHEMBL17737617 0.88 RECQL (0.69) RECQLIDO1KMT2AMEN1ALDH1A1
SCHEMBL17737362 0.87 IDO1 (0.62) RECQLIDO1KMT2AMEN1ALDH1A1
SCHEMBL17737441 0.87 IDO1 (0.62) RECQLIDO1KMT2AMEN1ALDH1A1
SCHEMBL19852954 0.87 IDO1 (0.62) RECQLIDO1KMT2AMEN1ALDH1A1
SCHEMBL15452718 0.87 IDO1 (0.62) RECQLIDO1KMT2AMEN1ALDH1A1
SCHEMBL17737767 0.86 IDO1 (0.67) RECQLIDO1KMT2AMEN1ALDH1A1
SCHEMBL17737365 0.85 IDO1 (0.63) RECQLIDO1KMT2AALDH1A1MAPT
SCHEMBL17737675 0.85 IDO1 (0.63) RECQLIDO1KMT2AMEN1ALDH1A1
SCHEMBL12220834 0.85 KCNA5 (0.52) RECQLIDO1KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3215155-B1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD (GB) 2020-10-14 EP disclosed
US-10287252-B2 Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase IOMET PHARMA LTD. (GB) 2019-05-14 US disclosed
US-20180037553-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD. (GB) 2018-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287252-B2 Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase TDO2, IDO2, IDO1 RECQL 1366/4885IDO1 3/4885KMT2A 1561/4885
US-20180037553-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE TDO2, IDO2, IDO1 RECQL 1366/4885IDO1 3/4885KMT2A 1561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.